Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease

• Status: Not yet recruiting
• Trial end date: 2024-05-20
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of the present study is to investigate whether intralesional injections of Hyaluronic acid in the acute phase could reduce the progression of Peyronie's disease thanks to its interference with inflammatory and pro-fibrotic processes.

Therefore, a prospective, longitudinal, double-blinded, randomized clinical study, has been designed to evaluate and compare the efficacy and safety of intralesional HA as compared with the use of verapamil injection in patients affected by Peyronie's disease.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benha University
• Treatments: Hyaluronic Acid; Verapamil

Criteria

Inclusion Criteria:

• Patient's age from >18 - 70 years old.

• A palpable nodule or plaque in the tunica of the penis

• Presence of pain in the flaccid state or during painful erections.

• Progressive penile curvature >15° and/or penile pain in the flaccid state or at the erection in the last 12 months

Exclusion Criteria:

• Patient refusal.

• Calcified plaques or hourglass deformity as defined at duplex Doppler ultrasonography,

• Previous Peyronie's Disease therapy with oral agents or intralesional injections

• Severe concomitant erectile dysfunction (International Index of Erectile Function [IIEF-5] score < 7).

• Congenital penile curvature, history of previous penile surgery, a concomitant oral treatment for Peyronie's Disease.